GLPwatch
Papers (9189)
Page 106 of 154, ranked by citation count.
- Inhibition of notch signalling and mesangial expansion by combined glucagon like peptide-1 agonist and crocin therapy in animal model of diabetic nephropathy.
- Editorial: Global Obesity Rates Continue to Rise with Challenges for New Drug Treatments Including GLP-1 Receptor Agonists.
- Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
- WHO Warns of Counterfeit Ozempic in the Global Supply Chain-Here's What to Know.
- The Modified Exenatide Microspheres: PLGA-PEG-PLGA Gel and Zinc-Exenatide Complex Synergistically Reduce Burst Release and Shorten Platform Stage.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
- Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
- [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
- Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.
- GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk.
- Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.
- Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue.
- Publicising trial results before peer review.
- Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.
- [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
- Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.
- The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.
- Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.
- Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats.
- Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals.
- The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide_A sensitivity analysis.
- Para-Tyrosine Supplementation Improves Insulin- and Liraglutide- Induced Vasorelaxation in Cholesterol-Fed Rats.
- Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.
- Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.
- Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study.
- The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide.
- Exenatide enhances INS-1 rat pancreatic β‑cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein.
- After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
- Acute Cholesterol-Lowering Effect of Exendin-4 in Ldlr<sup>-/-</sup> and C57BL/6J Mice.
- Semaglutide Improved Cardiovascular Health in People Without Diabetes.
- iGlarLixi for type 2 diabetes: a systematic review and meta-analysis.
- Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.
- [Exendin-4 ameliorates high glucose- and TNF-α-induced vascular endothelial cell damage by inhibiting p38 MAPK and NF-κB p65 translocation].
- Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective.
- Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.
- Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
- Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
- Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors.
- The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
- GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.
- Effects of exenatide in poorly controlled type 2 diabetes.
- A Study on Weight Loss Cause as per the Side Effect of Liraglutide.
- Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.
- Treatment of obese diabetics.
- Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.
- Current updates on pharmacological roles of glucagon-like peptide 1 in obesity.
- Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2.
- Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
- Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.
- Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
- Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita?
- In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae.
- GLP-1 Analog Alleviated Cognitive Dysfunction in Aged Rats Anaesthetized with Sevoflurane.
- Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.
- Glycaemic control and weight loss with semaglutide in type 2 diabetes.
- Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration.
- Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
- Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.